Patents by Inventor Karen Van Orden
Karen Van Orden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11802164Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: January 21, 2020Date of Patent: October 31, 2023Assignee: Celera CorporationInventors: Steve Ruben, Tao He, Candy Lee, Karen Van Orden, Paul Moore
-
Publication number: 20200291129Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 21, 2020Publication date: September 17, 2020Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20200276329Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: January 8, 2020Publication date: September 3, 2020Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20180265591Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 10, 2018Publication date: September 20, 2018Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20170350897Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: April 12, 2017Publication date: December 7, 2017Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20160161494Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: June 19, 2015Publication date: June 9, 2016Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20150361181Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 24, 2015Publication date: December 17, 2015Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20140314768Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: October 23, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140193419Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: July 10, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20130315915Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: Celera CorporationInventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Patent number: 8486392Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: October 8, 2010Date of Patent: July 16, 2013Assignee: Celera CorporationInventors: Steve Ruben, Paul Moore, Tao He, Candy N. Lee, Karen Van Orden
-
Publication number: 20120177659Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Publication number: 20110250204Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: October 8, 2010Publication date: October 13, 2011Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Paul A. MOORE, Tao HE, Candy N. LEE, Karen VAN ORDEN, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
-
Patent number: 7842291Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: May 22, 2007Date of Patent: November 30, 2010Assignee: Celera CorporationInventors: Steve Ruben, Paul A. Moore, Tao He, Candy N. Lee, Karen Van Orden, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
-
Publication number: 20100061977Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: July 17, 2009Publication date: March 11, 2010Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Publication number: 20100040637Abstract: Methods and compositions for detecting and treating diseases, especially cancer, and particularly breast, bladder, colon, gastrointestinal, kidney, liver, lung, melanoma, ovary, pancreatic, pharyngeal, prostate cancer and renal, associated with differential expression of prominin-1 (CD133) in disease cells compared to healthy cells. Also provided are antagonists or agonists of prominin-1, and methods for screening agents that modulate the prominin-1 level or activity in vivo or in vitro.Type: ApplicationFiled: November 22, 2006Publication date: February 18, 2010Inventors: Karen Van Orden, Maria Leai Smith, Albina Nesterova, Candy Lee, Steve Ruben